Registered Office: A-109 Express Apartments, Lakdi ka Pool, Hyderabad - 500004



Corporate Office: 5th floor, Prestige Phoenix, 1405, Uma Nagar, Begumpet, Hyderabad - 500016

+91 7780301502 • info@bankabio.com • www.bankabio.com • CIN: L90001TG2012PLC082811

10 August 2023

The Listing Department
National Stock Exchange of India Limited
Exchange Plaza C-1, Block G
Bandra Kurla Complex, Bandra (East)
Mumbai - 400051

Symbol: BANKA

Sub: Outcome of Board Meeting held on 10 August 2023.

Ref: Regulation 30 & 33 read with sub-para 4 of Para "A" of Part "A" of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Dear Sir/Madam.

With reference to the above-cited subject, we would like to inform you that the meeting of the Board of Directors of the Company held today i.e. 10 August 2023, the Board, inter alia, discussed, considered, and approved the:

- a) Un-audited financial results (both standalone and consolidated) for the quarter ended 30 June 2023.
- b) Limited Review Reports received from the Statutory Auditors thereon as on 30 June 2023.
- c) Sale of shares held in Sustainable Sanitation Industry Association (Associate Company).

Further, the Board of Directors have decided to defer the following agenda items due to time constraint:

- a) Approval of Board Report along with its annexures, for the year ended 31 March 2023.
- b) Review & Approval of the "Banka BioLoo Limited Employee Stock Option Plan 2023", subject to approval of members of the Company in the ensuing AGM.
- c) Fixing the date, time and venue for the 11th Annual General Meeting (AGM) of the Company, and approve the draft notice of AGM thereon

(Details of the ensuing Board meeting for considering aforesaid agenda(s) shall be informed separately),

The meeting commenced at 3:30 pm and concluded at 5:30 pm. These are also being made available on the website of the Company at www.bankabio.com

This is for your information and records.

Thank you

For Banka BioLoo Limited

Vishal Murarka CEO & Executive Director DIN: 06729485

Encls as above

BANKA BIOLOO LIMITED

Unaudited STANDALONE Statement of Financial Results for the quarter ended 30 June 2023

	Quarter Ended				Year ended
_		Unaudited	Audited	Unaudited	Audited
S. No	Particulars				
INO		30.06.2023	31.03.2023	30.06.2022	31.03.2023
1	Income				
	Revenue from Operations	810.83	1200.14	939.35	4214.3-2
	Other income	21.17	41.05	8.11	81.24
	Total Income	832.00	1241.19	947.46	4295.5 6
2	Expenses				
	Cost of materials consumed	292.66	354.41	174.80	787.29
	Changes in inventories of finished goods & work- in-				
	progress	43.79	3.95	(58.33)	(29.71)
	Employee benefits expense	514.42	559.36	541.07	2245.29
	Finance costs	40.98	12.17	41.33	133.1 6
	Depreciation and amortisation expense	41.86	56.27	31.12	143.3 8
	Other expenses	83.80	154.97	176.89	601.38
	Total expenses	1017.50	1141.14	906.87	3880.78
3	Profit/(loss) before tax	(185.50)	100.05	40.60	414.78
	F				
4	Tax expense	¥			
	(1) Current tax	-	(2.64)	3.55	55.4 1
	(2) Taxes for earlier years		24.98	_	24.98
	(3) MAT Credit		_	~	_
	(4) Deferred tax	(1.75)	34.18	(10.20)	26.75
	Total Tax expense	(1.75)	56.52	(6.64)	107.14
		` '		()	
5	Profit after tax	(183.75)	43.54	47.24	307.64
	Other comprehensive income				
	Items that will not be reclassified to profit and loss				
	Remeasurement of post-employment benefit				
	obligations	0.00	7.76	0.00	7.76
	Income tax effect on items that will not be reclassified	0.00	(1.95)	0.00	
	Other comprehensive income for the year	0.00	5.81	0.00	(1.95)
	, , , , , , , , , , , , , , , , , , , ,	0.00	3.01	0.00	5.81
	Total comprehensive income for the year	(183.75)	49.35	47.24	313.44
6	Daid we conitr the secretal (Feb. 1 - D. 10/	400444			
6	Paid up equity share capital (Face value Rs. 10/- each)	1084.66	1084.66	1084.66	1084.66
7	Earnings per share				
	Basic and Diluted Earnings per share (in Rs.)	(1.69)	0.40	0.44	2.84
		(Not	(Not	(Not	
	ii ii	annualised)	annualised)	annualised)	(Annualised)

FOR & ON BEHALF OF BOARD OF DIRECTORS

Vishal Murarka

CEO & Executive Director

DIN: 06729485

Place: Hyderabad Date: 10.08.2023

Notes:

- The above unaudited Standalone Financial Results were reviewed by the Audit Committee and then approved by the Board of Directors at their respective meetings held on 10 August 2023.
- 2. The Standalone Financial Results have been prepared in accordance with Indian Accounting Standards prescribed under section 133 of the Companies Act 2013 ("the Act") read with the relevant rules issued there under ("INDAS") followed consistently and other accounting principles generally accepted in India. The above Standalone Financial Results have been prepared in Compliance with Regulation 33 of SEBI (Listing Obligations and Disclosure requirements) Regulations 2015.
- 3. The Standalone Financial Results for the quarter ended 30 June 2023 have been prepared following the same accounting policies as those followed for the annual financial statements for the year ended 31 March 2023.
- 4. Based on the internal reporting provided to the Chief Operating Decision Maker, the standalon e financial results relate to the business of waste water & fecal treatment manufacture, supply and installation of and related AMOC services as the only reportable primary segment of the Company as per the Irad AS 108 "Operating Segments".
- 5. The figures of the quarter ended March 31, 2023 are the balancing figures between audited figures in respect of full financial year ended March 31, 2023 and the unaudited published year to date figures up to the end of the third quarter of respective financial year.
- 6. The Company has considered internal and external information up to the date of approval of these standalone financial results in assessing the recoverability of assets including trade receivables, unbilled receivables, based on which it expects to recover the carrying amount of these assets.
- 7. Figures of previous year / period have been regrouped / recast wherever necessary, in order to make them comparable.

Place: Hyderabad Date: 10 August 2023 For Banka Bioloo Limited

VICKEL FLUARE Vishal Murarka

CEO & Executive Director

DIN: 06729485

BANKA BIOLOO LIMITED

Unaudited CONSOLIDATED Statement of Financial Results for the Quarter ended 30 June 2023

•		•				
	n		1	1,	h	0

					In Lakns
		Quarter ended			Year ended
S. No	Particulars	30.06.2023 Unaudited	31.03.2023 Audited	30.06.2022 Unaudited	31.03.2023 Audited
1	Income				
	Revenue from Operations	827.55	818.28	1,110.23	4,234.98
	Other income	17.29	34.89	10.37	70.11
	Total Income	844.84	853.16	1,120.61	4,305.09
2	Expenses				,
	Cost of materials consumed	293.07	(54.29)	273.37	593.21
	Changes in inventories of finished goods & work- in-				
	progress	57.76	3.46	(68.57)	(39.35)
	Employee benefits expense	529.68	588.13	575.77	2,370.09
	Finance costs	50.80	17.62	46.47	154.81
	Depreciation and amortisation expense	45.94	57.68	32.33	148.25
	Other expenses	98.74	174.56	214.44	716.31
	Total expenses	1,075.98	787.14	1,073.81	3,943.32
3	Share of profit/(loss) of Associates	0.84	(6.70)	2.46	0.84
	¥				
4	Profit/(loss) before tax	(230.31)	59.32	49.26	362.61
5	Tax expense				
	(1) Current tax	4.88	(1.17)	3.55	56.88
	(2) Taxes for earlier years	-	24.98	-	24.98
	(3) MAT Credit	:=	-		-
	(4) Deferred tax	(1.78)	34.07	(10.20)	26.65
	Total Tax expense	3.10	57.88	(6.65)	108.51
6	Profit after tax	(233.40)	1.45	55.91	254.10
	Other comprehensive income Items that will not be reclassified to profit and loss Remeasurement of post-employment benefit obligations		7.76		7.76
	Income tax effect on items that will not be reclassified	_	(1.95)		(1.95)
	Other comprehensive income for the year	_	5.81		5.81
			5.02		5.51
	Total comprehensive income for the year	(233.40)	7.25	55.91	259.90
	Attributable to Shareholders of the Company Non controlling interest	(233.40)	7.25	55.91	259.90
7	Paid up equity share capital (Face value Rs. 10/- each)	1,084.66	1,084.66	1,028.89	1,084.66
8	Earnings per share Basic and Diluted Earnings per share (in Rs.)	(2.15) (Not	0.07 (Not	0.52 (Not	
	2 ON PENALE OF BOARD OF DARROTORS	annualised)	annualised)	annualised)	(Annualised)

FOR & ON BEHALF OF BOARD OF DIRECTORS

Vishal Murarka

CEO & Executive Director

DIN: 06729485

Place: Hyderabad Date: 10.08.2023

Notes:

- The above statement of unaudited Consolidated Financial Results was reviewed by the Audit Committee
 and then approved by the Board of Directors at their respective meetings held on 10 August 2023_
- 2. These Consolidated Financial Results have been prepared in accordance with Indian Accounting Standards prescribed under section 133 of the Companies Act 2013 ("the Act") read with the relevant rules issued there under ("INDAS") followed consistently and other accounting principles generally accepted in India. These Financial Results have been prepared in Compliance with Regulation 33 of SEBI (Listing Obligations and Disclosure requirements) Regulations 2015.
- 3. The consolidated financial results of the Group include the results of the Company and results of the following entities.

Name of the entity	Status
Enzotech Solutions Pvt Ltd	Wholly owned subsidiary
Megaliter Varunaa Pvt Ltd	Wholly owned subsidiary
Sustainable Sanitation Industry Association	Associate with 25% share to the Company
Sai Banka SPV Pvt Ltd	Associate with 50% share to the Company

- 4. The figures of the quarter ended March 31, 2023 are the balancing figures between audited figures in respect of full financial year ended March 31, 2023 and the unaudited published year to date figures up to the end of the third quarter of respective financial year.
- 5. The Company has considered internal and external information up to the date of approval of these Consolidated financial results in assessing the recoverability of assets including trade receivables, unbilled receivables, based on which it expects to recover the carrying amount of these assets.
- 6. Figures of previous year / period have been regrouped / recast wherever necessary, in order to make them comparable.

For Banka Bioloo Limited

Vishal Murarka

CEO & Executive Director

DIN: 06729485

Place: Hyderabad Date: 10 August 2023

PRSV&Co.LLP Chartered Accountants



202, Saptagiri Residency, 1-10-98/A, Chikot i Gardens,

Begumpet, Hyder abad - 500 016 Phone : +91 40 66108177/2776 68

Telefax : +91 40 2776 6881 E-mail : prsvco @gmail.com

Website: prsvllp_com

Independent Auditor's Review Report on the Quarterly Unaudited Standalone Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclos ure Requirements) Regulations, 2015, as amended.

To The Board of Directors of BANKA BIOLOO LIMITED

We have reviewed the accompanying Statement of unaudited standalone financial results of BAN KA BIOLOO LIMITED for the quarter ended June 30, 2023 (the "statement"), being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 ('the Regulation') as amended, read with SEBI Circular No.CIR/CFD/CMD1/44/2019 dated March 29, 2020 ('the Circular').

- 1. This Statement, which is the responsibility of the Company's management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review
- 2. We conducted our review of the statement in accordance with the Standards on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the statement is free from material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
- 3. Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying statement, prepared in accordance with the aforesaid Indian Accounting Standards prescribed under section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations including the manner in which it is to be disclosed, or that it contain any material misstatement.

For PRSV & Co. LLP

Chartered Accountants

Firm Registration No: S200016

Y.Venkateswarlu

Partner

Membership No: 222068

Place: Hyderabad Date: 10-08-2023

UDIN: 23222068BGTVWT6862

PRSV&Co.LLP Chartered Accountants



202, Saptagiri Re-sidency, 1-10-98/A, Chikotti Gardens,

Begumpet, Hyderabad - 500 016

Phone : +91 40 66108177/2776 688 Telefax : +91 40 2776 6881

Telefax: +91 40 2776 6881 E-mail: prsvco @gmail.com

Website: prsvllp_com

Independent Auditor's Review Report on the Quarterly Unaudited Consolidated F inancial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To
Board of Directors of BANKA BIOLOO LIMITED

- 1. We have reviewed the accompanying Statement of Unaudited Consolidated Financial R esults of BANKA BIOLOO LIMITED (The Parent") and its subsidiary (The parent and its subsidiaries and its associate together referred to as the "Group") for the quarter ended 30 June 202.3 ("the statement"), being submitted by the Parent Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 ('the Regulation') as amended, read with SEBI Circular No.CIR/CFD/CMD1/44/2019 dated March 29, 2019 ('the Circular').
- 2. This Statement, which is the responsibility of the parent's management and approved by the parent Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
- 3. We conducted our review of the statement in accordance with the Standards on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the statement is Free from material misstatement. A review is Limited primarily to inquiries of the Company personnel and analytical procedures applied to financial data and thus provides less assurance that an audit. We have not performed an audit and, accordingly we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 ('the Regulation') as amended to the extent applicable.

4. The Statement includes the results of the following entities.

Holding/Parent Company
BANKA BIOLOO LIMITED

Wholly Owned Subsidiary

ENZOTECH SOLUTIONS PRIVATE LIMITED MEGALITER VARUNAA PRIVATE LIMITED

Associate

SAI BANKA SPV PRIVATE LIMITED SUSTAINABLE SANITATION INDUSTRY ASSOCIATION



Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying statement, prepared in accordance with the aforesaid Accounting Standards prescribed under section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Regulation, read with the Circular, including the manner in which it is to be disclosed, or that it contains any material misstatements.

Other Matter

We did not review the interim financial information of 1 subsidiary included in the unaudited consolidated financial results, whose interim financial information reflect total revenues of Rs. 39.70 Lacs, total net loss of Rs.62.04 Lacs and total comprehensive loss of Rs. 62.04 Lacs for the quarter ended June 30, 2023, as considered in the statement. This interim financial information has been reviewed by other auditors whose reports have been furnished to us by the management and our conclusion on the statement in so far as it relates to the amounts and disclosures included in respect of the subsidiary is based solely on the reports of other auditors and the procedures performed by us as stared above.

We did not review the interim financial information of 1 subsidiary included in the unaudited consolidated financial results, which have not been reviewed by their auditor, whose interim financial information reflect total revenues of Rs. 105.20 Lacs, total net profit after tax of Rs.14.50 Lacs and total comprehensive income of Rs. 14.50 Lacs for the quarter ended June 30, 2023, as considered in the statement. The statement also includes financial results of 2 associate as mentioned above, whose share of net profit after tax of Rs. 0.84 Lacs and total comprehensive income of Rs. 0.84 Lacs for the quarter ended June 30, 2023, as considered in the unaudited consolidated financial results, based on their interim financial results which have not been reviewed and which has been furnished to us by the Management. According to the information and explanations given to us by the management, these unaudited interim standalone financial results are not material to the group.

For PRSV & Co LLP

Chartered Accountants

Firm Registration No. S200016

Y.Venkateswarlu

Partner

Membership No. 222068

Place: Hyderabad Date: 10-08-2023

UDIN: 23222068BGTVWU8419



Registered Office: A-109 Express Apartments, Lakdi ka Pool, Hyderabad - 500004

Corporate Office: 5th floor, Prestige Phoenix, 1405, Uma Nagar, Begumpet, Hyderabad - 500016 +91 7780301502 • info@bankabio.com • www.bankabio.com • CIN: L90001TG2012PLC082811

10 August 2023

The Listing Department
National Stock Exchange of India Limited
Exchange Plaza, Bandra Kurla Complex
Bandra (East)
Mumbai - 400051

Symbol: BANKA

Sub: Disinvestment in Sustainable Sanitation Industry Association (Associate Company)

Ref: Regulation 30 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 read along with SEBI Circular CIR/CFD/CMD/4/2015 dated July 13, 2023

Dear Sir/Madam,

With reference to the above-cited subject, we hereby inform you that, the Board of Directors of the Company, at their meeting held today i.e., on 10 August 2023, have considered and approved to disinvest in Sustainable Sanitation Industry Association (SSIA), by selling 20,000 (Twenty Thousand) equity shares of ₹10 each/- (i.e. 25 %) at par, for an aggregate sale consideration of Rs. 2,00,000 (Rupees Two Lakh Only).

Upon completion of aforesaid transaction, SSIA, shall cease to be an "Associate Company"

Detailed Disclosure pursuant to SEBI Circular SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023 in accordance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 is annexed as Annexure-1.

Kindly take the above information on records.

Thank you

For Banka BioLoo Limited

Vishal Murarka CEO & Executive Director DIN: 06729485

Encl: Annexure-1

Annexure 1

(Disclosure pursuant to SEBI Circular SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023)

Disclosure pursuant to Regulation 30 of SEBI (Listing Obligation and Disclosure Requirements) Regulation, 2015 read along SEBI Circular CIR/CFD/CMD/4/2015 dated July 13, 2023:

a)	the amount and percentage of the turnover or revenue or income and	Rs. 0 (Zero Rupee)		
	net worth contributed by such unit or division or undertaking or	[As there were no		
	subsidiary or associate company of the listed entity during the last	operations]		
	financial year;			
b)	date on which the agreement for sale has been entered into;	Not Applicable		
c)	the expected date of completion of sale/disposal;	20 August 2023		
d)	consideration received from such sale/disposal;	Rs. 2,00,000 (Rupees		
		Two Lakh Only)		
e)	brief details of buyers and whether any of the buyers belong to the	Ms. Rajini Tummuluri		
	promoter/ promoter group/group companies. If yes, details thereof;	(Not related to		
		promoter/ promoter		
		group/group		
		companies)		
f)	whether the transaction would fall within related party transactions?	Not applicable		
	If yes, whether the same is done at "arm's length";			
g)	whether the sale, lease or disposal of the undertaking is outside	Not applicable		
	Scheme of Arrangement? If yes, details of the same including			
	compliance with regulation 37A of LODR Regulations.			
h)	additionally, in case of a slump sale, indicative disclosures provided	Not applicable		
	for amalgamation/merger, shall be disclosed by the listed entity with			
	respect to such slump sale.			

For Banka BioLoo Limited

Vishal Murarka CEO & Executive Director

DIN: 06729485